Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Ground-Glass Opacity and Subsolid Nodule in a Chest CT Report: Is It Cancer or Is It an Infection?

Ground-Glass Opacity and Subsolid Nodule in a Chest CT Report: Is It Cancer or Is It an Infection?
In this article

Ground-Glass Opacity and Subsolid Nodule in a Chest CT Report: Is It Cancer or Is It an Infection?

When a chest CT report mentions “ground-glass opacity,” “ground-glass nodule” or “subsolid nodule,” many people immediately ask: “Is it cancer?” These phrases are not diagnoses but descriptions of the image: an area where lung tissue is slightly denser, yet the lines of the vessels and airways can still be seen through it. Temporary causes such as infection, bleeding and inflammation, and also early lesions on the lung adenocarcinoma spectrum that persist, can produce the same picture. What separates them is usually not a single CT but time: in a Korean screening cohort of 50,132 adults, 30.0% of subsolid nodules found at the first screening and 78.9% of those that appeared later resolved on their own. This article explains the language of the report, temporary and persistent causes, the Fleischner and Lung-RADS follow-up recommendations, and what is done for persistent lesions. Decisions about your own report belong to the physicians who see your images.

30.0% / 78.9%Spontaneous resolution of subsolid nodules found on the first CT / appearing later (Korea, 50,132 people)
6 mmFollow-up threshold in Fleischner; routine follow-up is not recommended for smaller single nodules
5 yearsTotal follow-up period for persistent subsolid nodules (Fleischner 2017)
66 / 70Screening cancers arising from ground-glass nodules that were stage 0 or I (94%)
Quick Answer · Clinician Summary
  • What does ground-glass mean? On CT, a slightly increased density in part of the lung through which vascular and bronchial structures are still visible. It is not a diagnosis but a description of the image. If round/oval and well defined, it is called a “ground-glass nodule”; if it also has a solid component, a “part-solid nodule”; together they are called “subsolid nodules.”
  • Cancer or infection? One CT cannot reliably tell them apart. Temporary causes such as infection and bleeding usually shrink or disappear on follow-up CT; persistent ones may be focal fibrosis or lesions on the adenocarcinoma spectrum (AAH, AIS, MIA, invasive adenocarcinoma).
  • How is it followed? Fleischner 2017 (incidental nodules): for a single pure ground-glass nodule ≥6 mm, CT at 6-12 months and, if it persists, every 2 years up to 5 years; for a single part-solid nodule ≥6 mm, CT at 3-6 months and, if it persists with a solid component <6 mm, annual CT for 5 years. If it persists and the solid component is ≥6 mm, it is considered highly suspicious.
  • What raises concern? Growth in size, increasing density, a new or growing solid component. Then a tumor board, PET/CT and biopsy or surgery come into discussion.
  • What it does not mean: It does not mean “they saw ground-glass, so it is cancer,” and it does not mean “it has been the same for years, so follow-up is no longer needed.” Both are inconsistent with guidelines and data.

What do the terms in the report mean?

Radiology reports can describe the same image in different words. The table below summarizes the most common phrases and what they mean in practice.

Phrase in the report Meaning Why it matters
Ground-glass opacity (GGO) Slightly increased lung density on CT; vessel and airway walls can still be seen A descriptive term; on its own it does not mean cancer. It may be focal or diffuse
Ground-glass nodule (GGN, pure ground-glass) A round or oval ground-glass area without a solid component May be temporary (infection, bleeding) or persistent (early adenocarcinoma spectrum, fibrosis)
Part-solid (mixed) nodule Contains a solid portion within the ground-glass that obscures vessels and airways The size of the solid component is one of the most important risk criteria
Subsolid nodule Common name for pure ground-glass and part-solid nodules Guidelines manage these two types separately
Consolidation / solid component A dense area that obscures the lines of vessels and airways May relate to invasion; its size is reported separately
Lung-RADS The ACR classification for lung cancer screening CT (categories 1-4) Routine, incidental CTs use Fleischner; the two are not the same

In the Fleischner guideline, nodule size is the average of the long and short axes, rounded to the nearest millimeter. A nodule is classified as part-solid only from 6 mm upward; for nodules smaller than 6 mm, follow-up is usually not required.

Figure 1 · Three appearances of a lung nodule

Ground-glass is a mild density that does not erase the vessel lines

Pure ground-glassvessels stay visiblePart-solidhas a solid centerSolidhides the vesselsSubsolid nodule
How to read it: In the pure ground-glass nodule (left) the density is mild and the vessel lines passing through it are visible. In the part-solid nodule (middle), there is a dark solid center within the ground-glass that hides the vessels. The solid nodule (right) hides the vessels completely. The first two together are called “subsolid nodules.” The diagram is simplified and is not a real CT image.

Where does ground-glass come from: temporary or persistent?

The ground-glass appearance is the shared result of very different processes: partial filling of the air-filled alveoli with fluid, cells, blood or tumor cells, or thickening of the walls. For this reason it is hard to guess the cause from the image, and looking again after some time is far more informative. For incidentally found subsolid nodules, the first question is: “Does it persist?”

Temporary causesProcesses such as infection (including viral and atypical pneumonias), alveolar hemorrhage, inflammation and organizing pneumonia. They usually shrink or disappear within weeks to months; that is why the first follow-up CT checks persistence.
Persistent, benignCauses such as focal fibrosis (a small scarred area). It persists on the image, but one CT cannot always separate it from lesions on the cancer spectrum.
Persistent, neoplasticAtypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma. They usually follow a very slow course.

Figure 2 · Spontaneous resolution of subsolid nodules

Low-dose CT screening cohort of 50,132 people in Korea (Thorax 2021). The bars show only these two percentages.

Nodules found at the first screening
30.0%
Nodules appearing later (new)
78.9%

In the same study, the frequency of subsolid nodules was 10.7% in never-smokers and 7.7% in ever-smokers. Of 293 nodules sampled by biopsy or surgery, 227 (77.5%) were lung cancer; because this group consists of suspicious nodules selected for sampling, it should not be read as the share of cancer among all ground-glass nodules.

Caution
  • For your nodule, the follow-up CT is decisive, not the percentages. The percentages above come from a single-center Asian cohort in which healthy people were screened; resolution is much more common in nodules that appear later.
  • Resolution or shrinkage should not be credited to a “course” of treatment or a medicine; temporary nodules also disappear on their own.

The cancer spectrum: from AAH to invasive adenocarcinoma

A significant share of persistent ground-glass nodules corresponds to the early and often very slowly progressing steps of lung adenocarcinoma. According to the IASLC/ATS/ERS classification and the WHO 2021 classification, the steps are these: atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS) are considered precursor lesions; minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma are separated by the presence of invasion. AIS is a tumor up to 3 cm with pure lepidic growth and no invasion; MIA is a lepidic-predominant tumor with a focus of invasion no larger than 5 mm.

Figure 3 · The adenocarcinoma spectrum and typical CT appearance

The dark center indicates the solid component

AAHAtypical adenomatous hyperplasiausually under 1 cm, pure ground-glassAISAdenocarcinoma in situ, up to 3 cmpure lepidic growth, no invasionMIAMinimally invasive adenocarcinomainvasion up to 5 mm, solid part commonInvasive adenocarcinomainvasion over 5 mmsolid component becomes prominent
How to read it: Moving from top to bottom, the ground-glass density of the nodule increases and the dark central solid component grows. AAH and AIS typically appear as pure ground-glass, while MIA and invasive tumors often appear part-solid; however, invasion may also be present in some pure ground-glass nodules. The diagram is simplified.

The signs considered “more invasive” on CT differ from study to study. In studies of resected pure ground-glass nodules, diameter thresholds for separating invasion were reported between 6.5 mm and 16.4 mm; that is, there is no exact line above which one can say “it is cancer.” In one study, about 10% of pure ground-glass nodules smaller than 10 mm also had foci of invasion. Imaging features linked with invasion include larger diameter and volume, an air bronchogram, lobulated or spiculated margins, and dilated vessels passing through the lesion. These are operated, selected series and cannot be applied as a rule to each patient.

Growth is usually very slow. That is why follow-up periods are long; but the reverse is also true: cases have been reported in which a ground-glass nodule stable for 5 years grew at 10-year follow-up. This shows that the 5-year limit in the guideline may not always be enough for an individual; the follow-up plan should be reviewed with your physician.

Follow-up guidelines: Fleischner 2017

The Fleischner Society’s 2017 recommendations apply to incidentally detected nodules in adults aged 35 and over. Screening CTs, immunosuppressed patients and patients with a known primary cancer are outside the scope. The table below summarizes the recommendations for subsolid nodules.

Finding Suggested approach Note
Single pure ground-glass nodule <6 mm No routine follow-up With suspicious morphology, CT at years 2 and 4 may be considered; with growth or a new solid component, resection is considered
Single pure ground-glass nodule ≥6 mm CT at 6-12 months to check persistence; if persistent, CT every 2 years up to 5 years In practice often expressed as checks at around years 1, 3 and 5
Single part-solid nodule <6 mm No routine follow-up A nodule can be classified as part-solid only from 6 mm upward
Single part-solid nodule ≥6 mm CT at 3-6 months to check persistence; if unchanged and the solid component is <6 mm, annual CT for 5 years If it persists and the solid component is ≥6 mm, it is considered highly suspicious
Multiple subsolid nodules <6 mm CT at 3-6 months; if stable, CT at years 2 and 4 is considered Multiple pure ground-glass nodules <6 mm are usually benign; in selected high-risk patients, follow-up at years 2 and 4 is considered
Multiple subsolid nodules ≥6 mm CT at 3-6 months; further management is set by the most suspicious nodule With multiple nodules, temporary (infectious, inflammatory) processes are considered more often

The table was compiled from the summary table of the Fleischner Society 2017 guideline. Recommendations from other bodies such as NCCN, CHEST, ACR and AATS may differ in size, solid component and timing; that is, a slightly different interval recommended at two centers is not a contradiction.

Figure 4 · Typical follow-up course for a single pure ground-glass nodule ≥6 mm

Fleischner 2017; timings are approximate and vary by person

Start
Nodule first seen
Thin-section CT; the diameter is measured and, if available, compared with old CTs.
Month 6-12
Checking persistence
If gone, a temporary cause is considered; if it persists, follow-up continues.
About year 3
Follow-up CT
Diameter, density and solid component are compared.
About year 5
Total period in the guideline
If unchanged, follow-up can end; your physician may extend it based on individual risk.

If growth, increased density or a new solid component appears, the plan changes without waiting: short-interval CT, tumor board, tissue diagnosis or surgery.

What does Lung-RADS (screening CT) say?

On low-dose CTs taken within lung cancer screening, Lung-RADS is used instead of Fleischner. According to the 2022 version (v2022), the categories for subsolid nodules and their approximate probabilities of malignancy are as follows.

Category Subsolid finding Approx. malignancy Suggested approach
2 (benign) Pure ground-glass <30 mm (or ≥30 mm that is stable or slow-growing); part-solid with total diameter <6 mm <1% Annual low-dose CT at 12 months
3 (probably benign) Pure ground-glass ≥30 mm (at baseline or new); part-solid with total diameter ≥6 mm and solid component <6 mm 1-2% Low-dose CT at 6 months
4A (suspicious) Part-solid with solid component ≥6 mm and <8 mm; new or growing solid component <4 mm 5-15% Low-dose CT at 3 months; PET/CT may be considered
4B (very suspicious) Part-solid with solid component ≥8 mm; new or growing solid component ≥4 mm >15% Diagnostic chest CT, PET/CT and/or tissue sampling

In Lung-RADS, growth means an increase of more than 1.5 mm in mean diameter within 12 months. A ground-glass nodule that doubles in size within a year is a feature that raises the category. Category numbers and probabilities were compiled from the search summary of the ACR document and secondary sources; for exact categorization, see the ACR version named in your report.

What is more reassuring, and what draws more attention?

More reassuringSmall diameter (<6 mm); pure ground-glass; shrinkage or disappearance on follow-up CT; multiple small pure ground-glass nodules; a recent respiratory infection.
More concerningIncrease in diameter; increase in density; a new or growing solid component; air bronchogram; lobulated or spiculated margin; dilated vessels entering the lesion.
Uncertain zoneNodules that stay stable for years; pure ground-glass nodules around 10 mm; several nodules. Here the decision is made not only from the guideline but also from age, general health, family history and patient preference.

What is done if it persists and is suspicious?

A persistent, suspicious subsolid nodule is evaluated in a tumor board of pulmonologists, thoracic surgeons, radiologists and medical oncologists. Because the metabolic activity of ground-glass nodules is low, the contribution of PET/CT is limited; Lung-RADS lists PET/CT among the options for nodules with a solid component of 8 mm or more. In choosing between biopsy, surgical removal and follow-up, the location of the nodule, the patient’s lung function and preferences are decisive.

If surgery is needed, operations that remove only part of the lung rather than a whole lobe have been shown to give good results in small, ground-glass-dominant tumors. Two Japanese studies support this:

Study Patients Operation Result
JCOG0804/WJOG4507L (single-arm, confirmatory phase 3) Peripheral, ≤2 cm, consolidation/tumor ratio ≤0.25; 333 enrolled Sublobar resection in 314 patients (258 wedge, 56 segmentectomy) 5-year relapse-free survival 99.7% (90% CI 98.3-99.9); no local relapse; grade ≥3 complications in 17 patients (5.4%)
JCOG1211 (single-arm, confirmatory phase 3) Ground-glass-dominant, ≤3 cm including ground-glass; 396 enrolled Segmentectomy in 357 patients At median follow-up of 5.4 years, 5-year relapse-free survival 98.0% (95% CI 95.9-99.1); grade 3-4 early complications in 7 patients (2%); no grade 5

Both studies were conducted in Japan, in selected patients and without a comparison arm; the results do not apply directly to every patient. Still, they show that surgery gives good results in early ground-glass-dominant tumors, and that when the operation is not urgent, the option of follow-up can also be discussed.

Latest data · 2026
  • A study published in February 2026 in Radiology: Cardiothoracic Imaging examined 1,724 people with a dominant ground-glass nodule in a CT lung cancer screening program. Lung cancer was diagnosed in 114 people; 70 (61%) arose from the dominant ground-glass nodule, and 66 of these (94%) were stage 0 or I. All 10 lung-cancer-related losses of life were from solid cancers unrelated to the ground-glass nodule.
  • In people with a ground-glass nodule, the likelihood of a cancer unrelated to the nodule was also higher than in those with Lung-RADS 1 (P=.007).
Limits
  • Guidelines are consensus texts: Fleischner 2017 is expert opinion without formal grading of evidence; there are differences between bodies.
  • Data rest on selected groups: surgical series represent only operated patients, and screening cohorts represent particular populations.
  • Percentages do not apply to an individual: resolution and cancer proportions vary with population, screening and nodule type.
  • This article is general information: decisions about your own report belong to the physicians who see your images.
Notes for Türkiye
  • Which system is named in the report? “Fleischner” is used for incidental nodules and “Lung-RADS” for screening CT. Turkish teaching materials also present the Fleischner 2017 table in the same way (ASYOD presentation).
  • Bring your old CTs: To assess growth, previous chest CTs (a CD or PACS access) are often the most valuable information; thin-section images are preferred.
  • Who evaluates? Specialists in pulmonology, thoracic surgery, radiology and medical oncology decide together.
  • A national nodule follow-up guideline or lung cancer screening program has not been confirmed in this article; clarify the follow-up plan with your treating physician.
  • If a cancer diagnosis is confirmed, the decision about molecular testing rests with your physician (what is next-generation sequencing (NGS)?, in Turkish).

Questions you can ask your doctor

  • Is my nodule pure ground-glass or part-solid; what is its diameter and, if present, the size of the solid component in mm?
  • Which system (Fleischner, Lung-RADS) was the report based on, and when is the first follow-up CT?
  • Has it been compared with my old CTs; is there growth or increased density?
  • If I recently had an infection, should the follow-up CT be done sooner?
  • For how many years in total will I be followed; at what finding would a tumor board or surgery come into discussion?

Common misconceptions

  • “If ground-glass is seen, it is cancer.” No. Temporary causes are very common; in the Korean screening data, 78.9% of new subsolid nodules resolved on their own.
  • “It has been the same for years, so follow-up is no longer needed.” No. Ground-glass nodules that were stable for 5 years and then grew have been reported; decide when to end follow-up together with your physician.
  • “PET/CT gives a definite answer for every nodule.” No. The metabolic activity of ground-glass nodules is low, and the value of PET/CT is limited.
  • “The nodule disappeared, so the medicine/course worked.” No. Temporary nodules also disappear on their own; do not draw a cause-and-effect link.

Frequently Asked Questions

Is ground-glass opacity cancer?
No, not by itself. Ground-glass is seen with temporary causes such as infection, bleeding and inflammation, and also with persistent lesions (fibrosis or lesions on the adenocarcinoma spectrum). A follow-up CT shows whether it persists.
How can infection be told apart from cancer?
One CT cannot reliably tell them apart. Infection and bleeding usually shrink or disappear on follow-up; persistence, growth, increased density or a new solid component point more toward the cancer spectrum. A history of recent infection helps the physician.
How often is a ground-glass nodule followed?
According to Fleischner 2017, for a single pure ground-glass nodule ≥6 mm, CT at 6-12 months and, if it persists, every 2 years up to 5 years is recommended; for a single part-solid nodule ≥6 mm, the first check is at 3-6 months. On screening CTs, Lung-RADS intervals are used. Your physician sets your own plan.
Does a ground-glass nodule need surgery?
Not always. For persistent and suspicious nodules that grow or develop a solid component, the tumor board discusses surgery. In Japanese studies of small ground-glass-dominant tumors, 5-year relapse-free survival of 98-99.7% was reported after sublobar surgery; these results apply to selected patients.
What does having several ground-glass nodules mean?
With multiple subsolid nodules, temporary infectious or inflammatory processes are considered more often; multiple pure ground-glass nodules smaller than 6 mm are usually benign. For those 6 mm or larger, CT is repeated at 3-6 months and management is set by the most suspicious nodule.
Are ground-glass nodules seen in non-smokers too?
Yes. In the Korean screening cohort, the frequency of subsolid nodules was higher in never-smokers (10.7%) than in ever-smokers (7.7%).

Glossary

Ground-glass opacity (GGO)
Slightly increased lung density on CT; vessel and airway structures remain visible.
Pure ground-glass nodule (pGGN)
A nodule without a solid component.
Part-solid nodule
A nodule that contains a solid component within the ground-glass.
Subsolid nodule
Common name for pure ground-glass and part-solid nodules.
Solid component
The dense part inside a nodule that obscures vessels and airways; often corresponds to the area of invasion.
AAH (atypical adenomatous hyperplasia)
A precursor lesion of adenocarcinoma; usually smaller than 1 cm and pure ground-glass in appearance.
AIS (adenocarcinoma in situ)
Adenocarcinoma up to 3 cm with purely lepidic growth and no invasion.
MIA (minimally invasive adenocarcinoma)
A small lepidic-predominant adenocarcinoma with an invasion area of no more than 5 mm.
Lepidic growth
Spread of tumor cells along the alveolar walls without destroying the existing structure.
Fleischner guideline
An international set of recommendations for following incidentally detected lung nodules (2017).
Lung-RADS
The ACR reporting system that classifies lung cancer screening CTs.
Sublobar resection
Removal of part of a lung lobe (wedge or segment) rather than the whole lobe.
Relapse-free survival (RFS)
The proportion or length of time patients remain free of relapse after treatment.

DROZDOGAN Academy Commentary

A ground-glass finding is not an “alarm signal” but “the start of follow-up”; time and comparison images supply the key information.

⚡ Why it matters

With the spread of chest CT, ground-glass findings are reported very often and can cause patients needless worry or, conversely, needless reassurance. The right question is not “is it cancer?” but “does it persist, does it change?”

✅ Strengths

The guidelines (Fleischner, Lung-RADS) are clear and usable; the frequency of temporary causes and the follow-up CT spare many patients unnecessary intervention; the results of sublobar surgery in small ground-glass-dominant tumors are very good.

⚠️ Limits

Guidelines are expert consensus and differ between bodies. The percentages come from single-center, predominantly Asian cohorts. One CT cannot reliably separate the causes; the 5-year limit may not be enough for everyone.

🩺 In practice

Take the report with your old CTs to a pulmonologist, thoracic surgeon or radiologist; get the measurements (diameter, solid component) and the follow-up plan in writing; do not miss the follow-up dates.

❓ Open questions

Which pure ground-glass nodules will really progress? In whom should follow-up extend beyond 5 years? Will artificial intelligence and radiomics be able to reduce the follow-up burden?

Conclusion: Ground-glass opacity is not a diagnosis but a follow-up question. The decision is made by observing persistence, growth, density and the solid component; make it together with the physicians who see your images, with timely follow-up checks.

Transparency note
  • This article was prepared in November 2026.
  • The Fleischner 2017 recommendations were checked against the guideline’s summary table (NYGH) and secondary summaries; the full text of the guideline was not examined directly here. The Lung-RADS v2022 thresholds and probabilities were taken from the search summary of the ACR document and secondary sources (Radiopaedia, radiogyan); small differences between the two sources were corrected according to the ACR document.
  • The Thorax 2021 (Korea) figures come from the article abstract; those from Hammer et al. (2026) from the search summary of the PubMed record and publisher page; and the JCOG0804 and JCOG1211 figures from published abstracts. The full texts were not examined directly here.
  • The figures are simplified and are not real CT images. The Academy commentary is our own.
  • This article is not medical advice; make decisions about your health together with your physician.

Sources

  1. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228-243. doi:10.1148/radiol.2017161659. pubs.rsna.org
  2. Fleischner Society 2017 Guidelines, summary table (NYGH). nygh.on.ca
  3. American College of Radiology. Lung-RADS v2022. November 2022. acr.org
  4. Kim YW, Kwon BS, Lim SY, et al. Lung cancer probability and clinical outcomes of baseline and new subsolid nodules detected on low-dose CT screening. Thorax. 2021;76:980-988. pmc.ncbi.nlm.nih.gov
  5. Hammer MM, et al. Clinical Outcomes of Ground-Glass Nodules Detected in a CT Lung Cancer Screening Program. Radiol Cardiothorac Imaging. 2026;8(1):e250293. doi:10.1148/ryct.250293. pubmed.ncbi.nlm.nih.gov
  6. Truong MT, Ko JP, Rossi SE, et al. Update in the Evaluation of the Solitary Pulmonary Nodule. RadioGraphics. 2014;34(6):1658-1679. doi:10.1148/rg.346130092. pubs.rsna.org
  7. Milanese G, Sverzellati N, Pastorino U, Silva M. Adenocarcinoma in pure ground glass nodules: histological evidence of invasion and open debate on optimal management. J Thorac Dis. 2017;9(9):2862-2867. doi:10.21037/jtd.2017.08.120. pmc.ncbi.nlm.nih.gov
  8. Tang ER, Schreiner AM, Pua BB. Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). J Thorac Dis. 2014 (PMID 25349701). pmc.ncbi.nlm.nih.gov
  9. Kobayashi Y, Mitsudomi T. Ground glass nodules with 5 years' stability can grow after 10-year follow-up: do genetic features determine the fate? (PMID 32038929). pmc.ncbi.nlm.nih.gov
  10. Suzuki K, Watanabe SI, Wakabayashi M, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer (JCOG0804/WJOG4507L). J Thorac Cardiovasc Surg. 2022;163(1):289-301.e2. pubmed.ncbi.nlm.nih.gov
  11. Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med. 2023;11(6):540-549. doi:10.1016/S2213-2600(23)00041-3. pubmed.ncbi.nlm.nih.gov
  12. Patel M, Bade B. Subsolid pulmonary nodules: From guidelines to real-world practice. CHEST Physician. chestphysician.org
  13. ASYOD. Toraks BT klinik yorumlama sunumu (2018). asyod.org

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Ground-Glass Opacity and Subsolid Nodule in a Chest CT Report: Is It Cancer or Is It an Infection?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy